We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $10.00 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Prior to today's trading, shares of the infectious disease drug developer had gained 7.77% outpaced the Medical sector's loss of 0.67% and the S&P 500's loss of 0.24%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. In that report, analysts expect Adma Biologics to post earnings of $0.19 per share. This would mark year-over-year growth of 18.75%. Meanwhile, our latest consensus estimate is calling for revenue of $139.8 million, up 4.16% from the prior-year quarter.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.78 per share and revenue of $536.82 million. These results would represent year-over-year changes of +30% and +5.22%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Adma Biologics currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 13.03. This indicates a discount in contrast to its industry's Forward P/E of 25.2.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 184, positioning it in the bottom 26% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Adma Biologics (ADMA - Free Report) closed at $10.00 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Prior to today's trading, shares of the infectious disease drug developer had gained 7.77% outpaced the Medical sector's loss of 0.67% and the S&P 500's loss of 0.24%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. In that report, analysts expect Adma Biologics to post earnings of $0.19 per share. This would mark year-over-year growth of 18.75%. Meanwhile, our latest consensus estimate is calling for revenue of $139.8 million, up 4.16% from the prior-year quarter.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.78 per share and revenue of $536.82 million. These results would represent year-over-year changes of +30% and +5.22%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Adma Biologics currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 13.03. This indicates a discount in contrast to its industry's Forward P/E of 25.2.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 184, positioning it in the bottom 26% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.